TKPHF - Takeda's rare bone cancer therapy fails late stage study

Takeda Pharmaceutical's (NYSE:TAK) late-stage study of its drug pevonedistat plus chemotherapy azacitidine failed as an initial treatment to prevent death in patients with a rare form of bone cancer. The phase 3 trial, dubbed PANTHER (Pevonedistat-3001), evaluated pevonedistat in combination  azacitidine as a first line as first-line treatment against the chemotherapy alone in patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myeloid leukemia. MDS are a group of are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The trial evaluated whether the combination therapy improved event-free survival (EFS) defined as death or transformation to AML in patients with higher-risk MDS or CMML, whichever occurs first. The Japanese company's drug pevonedistat — which works by inhibiting an enzyme, leading to cancer cell death — had received the U.S. Food and Drug Administration's breakthrough therapy designation in July 2020. “While

For further details see:

Takeda's rare bone cancer therapy fails late stage study